Its high expression is linked with a subset of AML patients with adverse-risk disease features and poor outcomes, with confirmation that high MEF2C mRNA expression leads to overexpression of MEF2C protein (Laszlo et al., 2015). This evidence concerns the gene MEF2C and acute myeloid leukemia.